These results further position the DIAMOND (TANTALUS) System as a beneficial and safe alternative to Insulin treatment for type 2 diabetics failing on oral medications.
Boston, MA (PRWEB) April 2, 2011
A new study suggests that the DIAMOND (TANTALUS) System developed by MetaCure might be a valid alternative to insulin in improving glycemic control and metabolic risk factors for suboptimally controlled obese T2DM without the associated weight gain.
In a poster presented at the 2nd World Congress on Interventional Therapies for Type 2 Diabetes held in New York on March 28-30, Dr. Simon Wong from the Department of Surgery at Prince of Wales Hospital in The Chinese University of Hong Kong demonstrated that as compared to insulin therapy, the DIAMOND System has the advantage of reducing body weight and waist circumference. It appears to be a safe alternative treatment option to insulin therapy in improving glycemic control.
An interim data analysis for eight patients was presented in the poster, four of which underwent DIAMOND System implantation and four treated with Insulin. Both groups experienced equivalent reduction in blood glucose levels; however, the DIAMOND (TANTALUS) treated group experienced weight loss and waist circumference reduction while the Insulin treated group experienced weight gain. The study is ongoing to collect additional data and follow up on patients.
Prof. Harold Lebovitz – Chairman of the MetaCure scientific advisory board said that these results further position the DIAMOND (TANTALUS) System as a beneficial and safe alternative to Insulin treatment for type 2 diabetics failing on oral medications.
About MetaCure – MetaCure is a medical device company dedicated to offering innovative minimally invasive solutions for metabolic and gastric conditions with a focus on type 2 Diabetes and obesity. The company's leading product, the DIAMOND System (formerly TANTALUS) has been shown to significantly improve glycemic and metabolic control. The DIAMOND (TANTALUS) System is CE approved since 2007 and is commercially available in select excellence centers in Europe.
# # #